Heme Oxygenase-1 Expression Affects Murine Abdominal Aortic Aneurysm Progression. by Azuma, Junya et al.
UC Office of the President
Recent Work
Title


















eScholarship.org Powered by the California Digital Library
University of California
RESEARCH ARTICLE
Heme Oxygenase-1 Expression Affects
Murine Abdominal Aortic Aneurysm
Progression
Junya Azuma1, Ronald J. Wong2*, Takeshi Morisawa2, Mark Hsu1, Lars Maegdefessel1,
Hui Zhao2, Flora Kalish2, Yosuke Kayama1,4, Matthew B. Wallenstein2, Alicia C. Deng1,4,
Joshua M. Spin1,4, David K. Stevenson2, Ronald L. Dalman3, Philip S. Tsao1,4
1 Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, United States
of America, 2 Department of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford
University School of Medicine, Stanford, CA, United States of America, 3 Division of Vascular Surgery,
Stanford University School of Medicine, Stanford, CA, United States of America, 4 Veterans Affairs Palo Alto
Health Care System, Palo Alto, CA, United States of America
* rjwong@stanford.edu
Abstract
Heme oxygenase-1 (HO-1), the rate-limiting enzyme in heme degradation, is a cytoprotec-
tive enzyme upregulated in the vasculature by increased flow and inflammatory stimuli.
Human genetic data suggest that a diminished HO-1 expression may predispose one to
abdominal aortic aneurysm (AAA) development. In addition, heme is known to strongly
induce HO-1 expression. Utilizing the porcine pancreatic elastase (PPE) model of AAA induc-
tion in HO-1 heterozygous (HO-1+/-, HO-1 Het) mice, we found that a deficiency in HO-1
leads to augmented AAA development. Peritoneal macrophages fromHO-1+/- mice showed
increased gene expression of pro-inflammatory cytokines, including MCP-1, TNF-alpha, IL-1-
beta, and IL-6, but decreased expression of anti-inflammatory cytokines IL-10 and TGF-beta.
Furthermore, treatment with heme returned AAA progression in HO-1 Het mice to a wild-type
profile. Using a secondmurine AAAmodel (Ang II-ApoE-/-), we showed that low doses of the
HMG-CoA reductase inhibitor rosuvastatin can induce HO-1 expression in aortic tissue and
suppress AAA progression in the absence of lipid lowering. Our results support those studies
that suggest that pleiotropic statin effects might be beneficial in AAA, possibly through the
upregulation of HO-1. Specific targeted therapies designed to induce HO-1 could become an
adjunctive therapeutic strategy for the prevention of AAA disease.
Introduction
Abdominal aortic aneurysm (AAA) disease is a potentially lethal condition that is character-
ized by the destructive remodeling of the infrarenal (IR) aorta [1]. It is a complex disease pro-
cess involving the infiltration of inflammatory cells, the production of reactive oxygen species
(ROS), upregulation and activation of degradative proteases, inactivation of nascent protease
inhibitors, stimulation of apoptosis, degradation of elastin, transmural inflammation, and
resistive hemodynamic conditions [2]. Currently, there is no effective medical or
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pharmaceutical intervention available for small AAAs that might delay or prevent the need for
invasive aneurysm repair.
One mechanism of particular interest is the flow-related upregulation of an anti-inflamma-
tory enzyme, heme oxygenase-1 (HO-1). Polymorphisms in the HO-1 promoter region have
been linked to AAA disease risk in humans [3]. Three isoforms of HO have been described.
Two (HO-2 and HO-3) are constitutively expressed, while HO-1 is inducible by inflammatory
stimuli. HO-1 degrades heme and produces equimolar concentrations of the bioactive prod-
ucts: carbon monoxide (CO), which is a vasodilator, ferrous iron, and biliverdin, which is rap-
idly converted to bilirubin by biliverdin reductase. Biliverdin and bilirubin are potent
antioxidants [4,5] and can protect the vascular endothelium and intima-media, and attenuate
lesion formation following injury. Other potential protective effects of HO-1 include a reduc-
tion of vascular smooth muscle cell (VSMC) proliferation, attenuation of vasoconstriction [6],
scavenging of free radicals, inhibition of platelet aggregation [7], and up-regulation of transfer-
rin expression with subsequent sequestration of oxidative free iron [8]. Although high levels of
HO activity (>15-fold) produce toxic, reactive iron species, moderate increases (<5-fold)
appear to be cytoprotective in animal models [9]. It has been shown that heme administration
can strongly upregulate HO-1 activity [10,11]. An increase in HO-1 gene expression has been
observed under high-flow conditions and associated with experimental AAA attenuation [12].
3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase) inhibitors (or statins)
are lipid-lowering agents that are widely used clinically [13]. Reduction of plasma lipids
through statins occurs by competitive inhibition of HMG-CoA reductase, an enzyme crucial
for cholesterol synthesis. Mechanisms beyond the reduction of plasma cholesterol levels con-
tribute significantly to the anti-atherogenic and tissue protective properties of statins. These
pleiotropic, cholesterol-independent benefits include anti-proliferative [14], immunomodula-
tory [14], vascular cytoprotection [15], angiogenic [16], plaque stabilizing [17,18], and antioxi-
dative effects [14,19], and anti-inflammatory properties [19,20]. While some trials have seen
no improvement in AAA progression in patients undergoing statin therapy [21], observational
studies and a meta-analysis suggest that statin therapy is associated with decreased expansion
rates in patients with small AAAs [22]. We previously demonstrated that statins induce HO-1
expression and reduce oxidative stress in vascular cells in vivo [23,24]. We hypothesize that
these properties of HO-1 may be one of the therapeutic effects of statins in ameliorating the
development of AAA disease.
Materials and Methods
Animals
Eight-week-old apolipoprotein E-deficient (ApoE-/-) male mice (n = 18) with a C57BL/6J back-
ground were purchased from Jackson Laboratories (Bar Harbor, ME). In our second set of
studies, 8-wk-old wild-type (WT, HO-1+/+, n = 14) and HO-1 heterozygous (HO-1 Het, HO-
1+/-, n = 13) FVB mice were used and purchased from Jackson Laboratories. For studies investi-
gating the effect of AAA development on HO-1 promoter activity, we used adult HO-1-luc
mice (8-wk-old), whose transgene contains the full-length HO-1 promoter fused to the
reported gene luciferase. All mice were provided with water and food ad libitum. All studies
were approved by the Stanford University Institutional Animal Care and Use Committee.
Angiotensin II-ApoE-/- AAA model
The subcutaneous osmotic angiotensin II (Ang II) infusion model was used to create suprare-
nal (SR) murine AAAs in the ApoE-/- mice. Under inhaled anesthesia with 2% isoflurane,
osmotic mini-pumps (Alzet Model 2004, Durect Corp., Cupertino, CA), prepared in sterile
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manner with Ang II (Sigma-Aldrich, St. Louis, MO) in saline, were inserted beneath the dorsal
skin of each mouse. Pumps were set to deliver Ang II at constant rate of 1000 ng/kg/min
[25,26]. All mice were then monitored daily for up to 28 days.
Porcine pancreatic elastase AAA model–HO-1+/- and C57Bl6 mice
The porcine pancreatic elastase (PPE) infusion model was used to induce IR AAAs as previ-
ously described [27] in WT and HO-1 Het FVB mice. In brief, after placing temporary ligatures
around the proximal and distal aortae, an aortotomy was created at the bifurcation, and a cath-
eter was inserted into the aorta and saline or saline containing type I PPE (1.5 U/mL, Sigma-
Aldrich) were infused for 5 min at 100 mmHg. After removing the infusion catheter, the aor-
totomy was repaired without constriction of the lumen. The health and condition of all mice
were monitored daily. At 14 or 28 days, the induced AAA (area between the left renal artery
and the bifurcation) was harvested. Samples were snap frozen in liquid nitrogen and then
stored at –80°C pending further processing. The survival rate through day 28 was> 80% for all
experimental groups. In those mice that did not survive, no clinical signs of ill health were
observed prior to death.
Statin treatment and experimental design–Ang II model
Rosuvastatin (AstraZeneca, Wilmington, DE) was dissolved in 30-μL polysorbate 80. Normal
saline was added to yield 100 mg/kg stock solutions. The saline vehicle was prepared similarly
without the addition of rosuvastatin. The dose of rosuvastatin was chosen to elicit pleiotropic
effects in the absence of lipid lowering as previously reported [23,24]. ApoE-/- mice undergoing
Ang II infusion were randomized and treated with daily intraperitoneal (IP) injections of saline
vehicle (n = 8) or rosuvastatin (n = 10) for 35 days, beginning 21 days prior to pump implanta-
tion. After this period of time, all animals were sacrificed and post-mortem measurements of
suprarenal (SR) and IR aortic diameters were performed. AAA severity was classified as fol-
lows: Type 1, SR/IR ratio< 2; Type 2, SR/IR ratio> 2; Type 3, presence of aortic dissection.
Measurements of serum total cholesterol, triglycerides, high-density lipoprotein (HDL), and
low-density lipoprotein (LDL) were performed using enzymatic assay kits.
Heme treatment–PPEmodel
HO-1 Het mice included in the PPE infusion AAA model were randomized to receive an IP
injection of vehicle (n = 6) or heme (60 μmol/kg BW, n = 7), which is a potent inducer of HO-1
[10,11], 1 day prior to and 14 days after PPE infusion.
HO activity–AAAmodels
Measurements of HO activity in both Ang II- and PPE-treated mice were performed as previ-
ously described [24,28]. Briefly, aortae were harvested following sacrifice, diluted in phosphate
buffer (1+9 v:v), diced with scissors, and sonicated at 50% power using a Microson Ultrasonic
Cell Disruptor (Misonix, Farmingdale, NY). Sonicates [20 μL, representing 2 mg fresh weight
(FW)] were incubated in CO-free septum-sealed vials containing 20 μL of 150-μMmethemal-
bumin (MHA) and 20 μL of 1.5-mM NADPH (blank reaction contained phosphate in place of
NADPH) for 30 min. Reactions were then terminated with the addition of 5 μL of 30% sulfosa-
licylic acid (SSA, Sigma-Aldrich). The amount of CO in the vial headspace was then quantified
by gas chromatography (GC). HO activity was calculated as pmol CO/h/mg FW, expressed as
fold change from saline-treated controls, and compared between all groups.
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Monitoring of AAA progression
Under inhaled anesthesia (2% isoflurane), maximum diameters in the transverse plane of the
aortae of all mice employed in the AAA model experiments were imaged using a Vevo 770
High-Resolution In Vivo Micro-Imaging System (VisualSonics, Toronto, CN) fitted with a
40-MHz transducer while placed in the supine position. The IR and SR aortae of rosuvastatin-
treated and control mice were measured at 0 and 14 days. The SR aortae were imaged prior to
pump implantation, AAA induction at day 0 and then at 7, 14, 21 and 28 days post-operatively,
Briefly, mice were first anesthetized with 5% isoflurane in 1 L O2/min and then maintained at
3% isoflurane in 1 L O2/min for the duration of the scan. Mice were kept warm on a heated
platform (37±0.5°C) connected to a temperature/physiology monitor (Indus Instrument,
Houston TX). Fur from the abdominal region was removed using a commercial hair remover
(Nair) and Ultrasound Transmission Gel (Parker Laboratories Inc., Fairfield, NJ) applied to
this area. The Power-Doppler mode was used to monitor blood flow velocities and pulse rates.
During the entire procedure, heart rates and rhythms, respirations, and body temperatures
were recorded. Aortic diameters were measured using transabdominal ultrasonography. Base-
line measurements were obtained 1 day prior to PPE infusion, and then every 7 days through
study completion at 28 days post-PPE infusion.
Immunohistochemical studies
Immunohistochemistry was performed to identify the cells expressing Mac1 and HO-1 pro-
teins. 6-μM thick sections were cut from paraffin-embedded aortae. After deparaffinization,
sections were treated for endogenous peroxidases with 0.03% H2O2 and blocked in 1% BSA
and 5% normal goat serum, then incubated with a primary antibody against Mac1 (1:200,
Abcam, Cambridge, MA) or HO-1 followed by the anti-rabbit immunoglobulin G (IgG) sec-
ondary antibody (1:200, BA-1000; Vector Labs, Burlingame, CA). Antibodies were then
detected using the Vector ABC kit (Elite Vectastain ABC kit; Vector Labs) and colorized with
0.05% diaminobenzidine (DAB; Vector Labs). Negative controls were run in parallel using
adjacent sections incubated with IgG instead of the primary antibody.
Thioglycollate-elicited macrophages and HO activity in vitro
Five days after IP injection of 3-mL 3% thioglycollate, primary peritoneal macrophages were
harvested from age-matched WT and HO-1 Het mice via IP lavage with phosphate-buffered
saline. Cells were plated in 10% fetal bovine serum with Dulbecco’s modified eagle medium
with 1% penicillin-streptomycin in 6-well plates. Cells were harvested for RNA isolation 6h
after plating.
RNA quantification
Total RNA was isolated using a TRIzol-based (Invitrogen, Carlsbad, CA) RNA isolation proto-
col and was quantified by Nanodrop (Agilent Technologies, Santa Clara, CA). Samples
required 260/280 ratios>1.8. The iScript cDNA synthesis kit (Bio-Rad) was used to synthesize
first-strand cDNA according to the manufacturer’s protocol. TaqMan qRT-PCR assays were
performed using mouse-specific primers (Applied Biosystems Inc., Foster City, CA). All probes
were normalized to 18S as a multiplexed internal control. Amplification took place on either a
PRISM 7900HT or a QuantStudio12K Flex (Applied Biosystems). All fold changes were calcu-
lated by the method of ΔΔCt, and are expressed as mean±SD compared to controls. All experi-
ments included 5 to 12 samples per group and time point.
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Statistical analyses
Data were presented as mean±SD and were analyzed using unpaired t-tests and non-paramet-
ric Mann-Whitney tests for the in vivo studies. Statistical significance was set at p<0.05.
Results
Diminished HO-1 activity increases AAA and increases macrophage
infiltration
As expected, total basal HO activity in the livers (90±4 pmol CO/h/mg FW, n = 10) and aortae
(22±1 pmol CO/h/mg FW, n = 3) of HO-1 Het mice were significantly lower compared to WT
mice (113±1, n = 4, p0.006 and 29±5 pmol CO/h/mg FW, n = 3, p0.05, respectively, Fig 1A
and 1B, left panels). After PPE infusion, there were significant increases in HO activity only in
the livers (176±7 pmol CO/h/mg FW, n = 3) and aortae (52±6 pmol CO/h/mg FW, n = 4) of
heme-treated HO-1 Het mice compared to HO-1 Het controls (p0.025).
Fig 2 shows the rate of abdominal aortic diameter enlargement after PPE infusion at days 3,
7, 14, 21, and 28 post-PPE infusion. We found that the size of aortic diameters significantly
increased in HO-1 Het mice compared to WT mice beginning day 7, and progressively signifi-
cantly increasing from days 14, 21, and 28 (45.0±7.6%, 64.8±15.3% (p = 0.010), 67.7±13.4%
(p<0.015), and 78.6±15.8% (p<0.003) for HO-1 Het mice versus 27.9±6.5%, 44.1±12.8%,
47.5±15.8%, and 50.5±16.0% for WT mice.
Immunohistochemical studies demonstrated that Mac1 staining in HO-1 Het mice was greater
than that forWTmice during AAA formation, indicating an increase in the infiltration of tissue
macrophages and decrease by day 28 (Fig 3A and 3B). In contrast, high levels of HO-1 staining
were observed in the macrophages of WTmice 7 days post-PPE infusion (data not shown).
Fig 1. HO activity. Total HO enzyme activity (pmol CO/h/mg FW) in the (A) livers and (B) aortae of WT (white bars), HO-1 Het (black bars), and heme-
treated HO-1 Het (grey bars) mice 28 days after PPE infusion (Post-PPE) and age-matchedWT and HO-1 Het controls. *p0.006, †p<0.025, **p0.05.
Number of animals in each group are shown in parentheses.
doi:10.1371/journal.pone.0149288.g001
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Furthermore, an increase in HO-1 promoter activity in the aorta (~10-fold) was observed
14 days post-PPE infusion in HO-1-lucmice (Fig 4A) compared to age-matched, saline-infused
control mice (Fig 4B).
Heme injection limits experimental AAA development
Induction of HO-1 in HO-1 Het mice by IP administration of heme resulted in an increase in HO
activity in livers (Fig 1A, left panel) and aortae (Fig 1B, left panel) and reduced the progression of
AAA in response to PPE to a level similar to that for WTmice at 7, 14, 21, and 28 days post-PPE
infusion (Fig 2). These differences began to manifest by day 7 and were significant by day 14 post-
PPE infusion from that observed in untreated HO-1 Het mice. Interestingly, in heme-treatedWT
mice rate of AAA enlargement was slightly higher than that for heme-treated HO-1 Het andWT
control mice. In addition, induction of HO-1 in HO-1 Het mice by heme administration resulted
a 77% reduction (53±10 cells/hpf) in infiltrating macrophages compared to untreated HO-1 Het
mice (231±79 cells/hpf, p<0.0001) at 28 days post-PPE infusion (Fig 3A and 3B).
HO-1 deficiency results in a decreasedmacrophage inflammatory response
Thioglycollate-elicited peritoneal macrophages from HO-1 Het mice exhibited increased levels
of mRNA expression of numerous pro-inflammatory cytokines, including MCP1, TNF-alpha,
Fig 2. Profiles of AAA development following PPE infusion. (A) AAA diameters were measured at baseline and at 3, 7, 14, 21, and 28 days post-PPE
infusion by ultrasound in WT (white squares), HO-1 Het (black squares), heme-treatedWT (white diamonds), and heme-treated HO-1 Het (black circles)
mice. (B) Representative longitudinal ultrasound views of AAAs 28-days post-PPE infusion from HO-1 Het, heme-treated HO-1 Het, WT, and heme-treated
WTmice. *p<0.015, †p = 0.0025 compared to WT and heme-treated HO-1 Het mice. n = 7 to 11 for each group.
doi:10.1371/journal.pone.0149288.g002
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IL-1-beta, and IL-6 (Fig 5A–5D), but had decreased levels of mRNA expression of anti-inflam-
matory cytokines IL-10 and TGF-beta (Fig 5E and 5F) as well as the macrophage protein
Ym1). As expected, HO-1 mRNA levels were decreased in HO-1 Het mice (Fig 5H).
Statin treatment limits AAA progression
Statin and vehicle-treated ApoE-/- mice did not differ in their body weights or lipid profiles
(including total cholesterol, triglycerides, HDL, and LDL) at the end of the time-course (Fig 6).
Fig 3. Immunohistochemical staining. (A) Immunohistochemical staining for Mac1 in aortae harvested fromWT and HO-1 Het mice at 7 and 28 days post-
PPE infusion and of heme-treated HO-1 Het mice at 28 days post-PPE infusion. (B) Macrophage infiltration in the aortae of WT (n = 4 and 7) and HO-1 Het
(n = 4 and 7) mice at 7 and 28 days post-PPE infusion, respectively, and of heme-treated HO-1 Het mice (n = 5) at 28 days post-PPE infusion (right panel).
Data shown as cells per high power field (hpf). *p<0.0001 compared to WTmice.
doi:10.1371/journal.pone.0149288.g003
Fig 4. HO-1 promoter activity in the aorta following PPE infusion in HO-1-lucmice. Ex vivo images taken 14 days following (A) saline infusion (control)
showing weak HO-1 promoter activity (low light intensity), and post-PPE infusion (B) showing high HO-1 promoter activity (strong light intensity) in the aorta.
doi:10.1371/journal.pone.0149288.g004
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Fig 7 shows that rosuvastatin treatment significantly reduced the size of AAA development by
32% compared to vehicle only-treated (2.3±0.2 versus 1.6±0.2 mm, respectively, p<0.04).
When total HO enzyme activity was measured in the aortae of vehicle- and rosuvastatin-
treated mice, no significant difference was found between the two groups (42.6±19.1 (n = 6)
versus 51.2±19.2 pmol CO/h/mg FW (n = 9), respectively, Fig 8). However, when AAA was
categorized by severity, we found that HO activity following type 2 and 3 AAA expansions
Fig 5. mRNA levels of the pro-inflammatory cytokines. Thioglycollate-elicited peritoneal macrophages from HO-1 Het mice exhibited significantly
increased mRNA levels of MCP1 (A), TNF-alpha (B), IL-1-beta (C), and IL-6 (D) as measured using RT-PCR. In contrast, mRNA levels of anti-inflammatory
cytokines IL-10 (E) and TGF-1 (F) were significantly lower. Moreover, YM-1 (G), one of the M2macrophage markers, was significantly lower in HO-1 Het
mice. As expected, HO-1 (H) levels were lower in HO-1 Het mice. *p<0.05, n = 3 to 5 for each group.
doi:10.1371/journal.pone.0149288.g005
Fig 6. Body weight and lipid profiles. 5 wks after Ang II infusion, body weight (A) and lipid (B) profiles were measured in vehicle- (white squares, n = 10)
and rosuvastatin- (black squares, n = 9) treated ApoE-/- mice. No significant differences were found between the 2 groups.
doi:10.1371/journal.pone.0149288.g006
HO-1 Attenuates AAA Progression
PLOS ONE | DOI:10.1371/journal.pone.0149288 February 19, 2016 8 / 14
were significantly higher in the rosuvastatin group (31.0±9.7 versus 58.1±19.1 and 65.9 versus
86.6 pmol CO/h/mg FW, respectively, p<0.05).
Discussion
The etiology of AAA formation is complex and multifactorial [29]. Prior studies have shown
that AAA development is associated with a profound inflammatory response and resultant
degradation of the extracellular matrix [29–31]. In the PPE murine AAA model, it is this
inflammatory process, and not the infusion of PPE itself, that leads to aneurysmal dilatation
[32]. Not surprisingly, administration of drugs that target specific points in the inflammatory
cascade have been shown to reduce AAA progression in experimental models–but thus far this
has not been shown in patients with AAA disease [33–35].
Studies of HO-1 knockout mice and human HO-1 promoter polymorphisms have demon-
strated that HO-1 is central to the antioxidant defense of vascular tissues [36–38]. As a result,
Fig 7. Effect of rosuvastatin on AAA severity. (A) Representative ex vivo pictures of aortas harvested from ApoE-/- mice treated with saline-vehicle (left
panel) or rosuvastatin (right panel) following Ang II infusion. (B) Number of pups categorized by AAA severity scores post-Ang II infusion in vehicle- (white
squares) or rosuvastatin- (black squares) treated mice. (C) Overall AAA severity in both groups combined. *p = 0.04, n = 7 and 9 for vehicle- and
rosuvastatin-treated mice, respectively.
doi:10.1371/journal.pone.0149288.g007
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several studies have investigated the role of HO-1 in relation to AAA. In humans, Schillinger
et al [3] reported that the length of a (GT)n repeat in the HO-1 gene promoter modulates the
level of HO-1 gene transcription, with short (GT)n repeats associated with increased HO-1
expression in response to inflammatory stimuli. They found that fewer AAA patients tended to
have these beneficially shorter repeats when compared to age- and sex-matched patients with
coronary or peripheral artery disease. Although a decreased ability to upregulate HO-1 may be
a risk factor, it is likely that in most cases, other conditions (genetic or environmental) that
may predispose an individual to a pro-inflammatory disposition, would in combination
increase risk. In fact, the presence of a stressor may be required to reveal this phenotype.
In a preclinical animal model of AAA disease, we previously showed that increases in local
blood flow results in smaller AAA diameters, and microarray analyses and confirmation by
RT-PCR indicated that HO-1 is significantly upregulated during this process. In addition, flow
loading has been shown to result in reduced ROS production [12]. These results are of interest
because of the reported role of HO-1 in oxidative stress [39]. Heme degradation by HO leads to
the generation of biliverdin, which is converted by biliverdin reductase to form bilirubin [40]. Bil-
iverdin and bilirubin have been shown to be efficient scavengers of ROS and are important to cel-
lular defense mechanisms against oxidative tissue injury [41,42]. Likewise, CO, another HO
byproduct, is a well-known anti-apoptotic, anti-inflammatory, and anti-proliferative molecule
that has been investigated for protecting against injury in the cardiovascular and respiratory sys-
tems [6,37]. For these reasons and because HO-1 is highly conserved and widely expressed in
human and animal cells, we hypothesized that it could serve as a therapeutic target.
Using the PPE model, we found that HO-1 was induced during AAA formation in WT
mice, but significantly less so in HO-1-deficient (Het) mice. In addition, HO-1 Het mice
showed an augmented development of AAA and an increased local infiltration of macro-
phages. Peritoneal macrophages isolated from these mice showed the expected diminished
Fig 8. Effect of rosuvastatin on HO activity and AAA severity. No significant difference in HO activity between aortas from vehicle- (white squares) and
rosuvastatin- (black squares) treated ApoE-/- mice were found 14 days post-Ang II infusion, but when grouped by severity, HO activity in aortas with type-2
expansions was significantly higher in rosuvastatin-treated mice. *p<0.05, n = 3 for each group.
doi:10.1371/journal.pone.0149288.g008
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HO-1 expression as well as an increased expression of inflammatory cytokines and a decreased
expression of protective cytokines. Moreover, induction of HO-1 expression in HO-1 Het mice
via heme treatment increased HO activity to near WT baseline levels and attenuated AAA
development, with aneurysm growth profiles approaching that seen for WT mice. Further-
more, heme treatment also reduced macrophage infiltration in AAA-induced HO-1 Het mice,
highlighting that the induction of HO-1 leads to anti-inflammatory responses and reduces a
pro-inflammatory response. Interesting, we observed that heme treatment to WT mice did not
attenuate AAA enlargement, and in fact, AAA size approached that of HO-1 Het levels. This
may be due to the fact that an over-induction of HO-1 may be detrimental as well as the fact
that the high dose of heme used may have been toxic. In contrast, heme treatment to HO-1 Het
mice may was able to induce HO-1 expression to basal levels observed in WT mice and pro-
vided protection.
Several studies have demonstrated a beneficial effect of statins in animal AAA models. Sim-
vastatin was shown to decrease both AAA incidence and aortic diameters in both WT and
ApoE-/- mice following PPE perfusion [43]. This statin was also shown to decrease AAA diam-
eters, MMP-9 and NF-kappa B protein levels, and microarray gene clusters related to inflam-
mation, extracellular matrix remodeling, and oxidative stress function in PPE-perfused rats
[44]. In humans, it has been shown that over a median period of 3.1 yrs in patients diagnosed
with AAAs, statin use resulted in a 1.16 mm/yr lower AAA diameter growth rate compared to
non-statin users [45]. Protein analyses of AAA aortic walls in patients randomized to simva-
statin therapy before undergoing open repair had lower levels of MMP-3 and MMP-9 [46].
Cellular analyses of their AAA walls further confirmed that statin use significantly reduced
MMP9 levels [47,48]. Notably, these clinical findings are considered controversial, since these
positive outcomes have not been replicated in larger and more rigorously performed studies.
Still, these overall findings in both human and experimental models of AAA disease do suggest
that statins may have potential to beneficially affect the pathogenesis of AAA.
Statins are well known to have pleotropic, tissue-protective effects in a manner independent
of its cholesterol-lowering properties. We have previously shown that HO-1 is a functionally
relevant target of several structurally different statins in endothelial cells suggesting a class
effect of these HMG-CoA reductase inhibitors. For all statins tested, an increase in HO-1
expression was observed and verified at both the transcriptional and translational levels
[49,50]. For simvastatin, induction of HO-1 protein in vascular smooth muscle cells was
reported by Lee et al [51]. HO-1 induction and associated biological effects, such as antioxidant
tissue protection occurred at clinically effective concentrations of statins. As a consequence of
this genomic action, cells were protected from oxidative stress [49,50]. Unlike other pleiotropic
effects of statins, HO-1 induction does not seem to depend on the inhibition of HMG-CoA
reductase and decreased formation of isoprenoids that are important for small G-protein acti-
vation [19]. In these studies, the addition of the HMG-CoA product mevalonate or the isopren-
oid farnesylpyrophosphate did not attenuate the response of HO-1 to statins [49,50],
precluding the involvement of isoprenoid-dependent pathways such as blockade of Rho and its
downstream target Rho kinase [52,53]. Based on this evidence, we believe that statin-depen-
dent HO-1 induction occurs in vascular and non-vascular tissues in vivo.
Our study indicates that some of these protective properties of statins likely derive from
their ability to effectively induce HO-1 expression. Rosuvastatin administration reduced AAA
progression in the Ang II model, and increased HO enzyme activity, independent of changes in
lipid profile. These results are consistent with our previous findings that statin administration
induces HO-1 in heart and lung tissues [23]. Taken together, these data suggest that the sup-
pression of AAA progression with statin administration is mediated, at least in part, by some of
the cytoprotective properties of HO-1. Future studies elucidating if the mechanism is mediated
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by the effects of HO-1 alone or via other anti-inflammatory or antioxidative processes is war-
ranted and beyond the scope of these studies.
In summary, we provide evidence of a crucial role of HO-1 in limiting aneurysm growth by
showing that HO-1 induction by heme slows AAA progression, confirming prior reports of
suppression of AAA progression with statin administration, and demonstrating that the statin
therapeutic mechanism likely involves the induction of HO-1 and likely independent of lipid
lowering. Therefore, development of specific targeted therapies that induce HO-1 expression
may be a new therapeutic strategy for the management of AAA disease as well as other inflam-
matory vascular diseases, such as atherosclerotic disease in other vessels.
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